Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sar-260301. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 0.83 |
| ▸ | AKT1 | P31749 | 20/20 | 0.83 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.83 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.83 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.83 |
| ▸ | PRKDC | P78527 | 1/20 | 0.83 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sar-260301 SCHEMBL12476155 | 0.93 | AKT1 (0.77) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Sar-260301 SCHEMBL1027765 | 0.91 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Sar-260301 SCHEMBL1030955 | 0.91 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Sar-260301 SCHEMBL1030883 | 0.91 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Sar-260301 SCHEMBL12476703 | 0.90 | AKT1 (0.84) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| Sar-260301 SCHEMBL12475696 | 0.86 | AKT1 (0.83) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12475784 | 0.84 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12475789 | 0.84 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12475817 | 0.82 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15318789 | 0.82 | AKT1 (1.00) | AKT1PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | PIK3CB 4/4885AKT1 13/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.